Skip to main content
E

EDX Medical Group Plc — Investor Relations & Filings

Ticker · EDX ISIN · GB00BNDMJS47 LEI · 213800BZVJZTMCZ6DJ63 Aquis Stock Exchange Human health and social work activities
Open in API
Filings indexed 112 across all filing types
Latest filing 2025-12-23 Director's Dealing
Country GB United Kingdom
Listing Aquis Stock Exchange EDX

About EDX Medical Group Plc

https://edxmedical.com/

EDX Medical Group Plc develops and provides digital diagnostic products and services for healthcare professionals. Its solutions are designed for the rapid detection and characterization of major diseases, enabling personalized treatment and improved patient outcomes. The company's primary focus areas are oncology, cardiology, and infectious diseases. Key offerings in oncology include comprehensive tumour profiling using whole exome and transcriptome sequencing, liquid biopsy analysis, and functional ex vivo assays that predict tumour response to specific therapies. The company also develops highly sensitive tests for early detection of cancers such as prostate and testicular cancer. In infectious diseases, EDX Medical develops point-of-care multiplex tests for conditions like sepsis and pneumonia. The company's approach integrates advanced molecular biology, genomic sequencing, and digital technologies across its laboratory-based services and point-of-care devices.

Recent filings

Filing Released Lang Actions
Director dealing
Director's Dealing Classification · 1% confidence The document is an official announcement regarding share purchases by the CEO (Dr. Michael Hudson) and a person closely associated with him. It explicitly uses the header 'Director dealing' and provides the required regulatory disclosure tables under the EU Market Abuse Regulation (MAR). This fits the definition of a Director's Dealing report.
2025-12-23 English
Interim report: Six months to 30 September 2025
Interim / Quarterly Report Classification · 1% confidence The document is titled 'Interim report: Six months to 30 September 2025' and contains comprehensive financial statements, including a condensed consolidated statement of total comprehensive income, statement of financial position, and statement of changes in equity. It provides substantive financial data and analysis for a period shorter than a full fiscal year, meeting the criteria for an Interim/Quarterly Report (IR). H1 2025
2025-12-19 English
Commercial launch of bowel cancer testing service
Regulatory Filings Classification · 1% confidence The document is a regulatory announcement issued via the London Stock Exchange's RNS (Regulatory News Service). It details the commercial launch of a new medical testing service by EDX Medical Group PLC. Since this is a general corporate announcement regarding business operations and product launches that does not fit into specific categories like financial reports, M&A, or director dealings, it falls under the 'Regulatory Filings' (RNS) category.
2025-12-18 English
Total Voting Rights
Declaration of Voting Results & Voting Rights Announcements Classification · 1% confidence The document is a 'Total Voting Rights' announcement issued by EDX Medical Group PLC. It specifies the total number of ordinary shares in issue and the associated voting rights, which is a standard regulatory requirement under the Financial Conduct Authority's Disclosure and Transparency Rules. Since this document does not fit into specific categories like 'Major Shareholding Notification' (which is for external parties) or 'Share Issue' (which describes a change in capital structure rather than just the current denominator), it falls under the general regulatory announcement category.
2025-10-31 English
EDX Medical secures up to £4million funding
Share Issue/Capital Change Classification · 1% confidence The document is an official announcement from EDX Medical Group plc regarding a capital raise of up to £4 million through the issuance of new ordinary shares and a convertible loan note. It details the share issuance, the related party transaction involving a director, and the total voting rights following the transaction. This fits the definition of a 'Share Issue/Capital Change' (SHA) as it describes the issuance of new shares and capital structure changes, and it is presented as a regulatory news service (RNS) announcement.
2025-10-20 English
Advance testicular cancer testing service launched
Regulatory Filings Classification · 1% confidence The document is a press release issued via the Regulatory News Service (RNS) by EDX Medical Group PLC. It announces the commercial launch of a new medical testing service (TC100). It does not fit into specific categories like financial reports, board changes, or shareholder voting results. As it is a general corporate announcement regarding business operations and product launches, it falls under the 'Regulatory Filings' (RNS) category as the appropriate fallback.
2025-10-07 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.